Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Arcturus' Investigational Inhaled Therapy Lacks Meaningful Lung Function Improvement, Analyst Notes Mixed Picture

Lung research

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) stock was trading lower on Wednesday after the company shared interim results from its ongoing Phase 2 trial of ARCT-032, an investigational inhaled mRNA therapy for cystic fibrosis.

In the second cohort of the study, six Class I CF adults received inhaled 10 mg doses of ARCT-032 daily over 28 days. The treatment was generally safe and well-tolerated.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.